Journal of Oral and Maxillofacial Surgery
Volume 67, Issue 5, Supplement , Pages 85-95 , May 2009

The Role of Surgical Resection in the Management of Bisphosphonate-Related Osteonecrosis of the Jaws

  • Eric R. Carlson, DMD, MD

      Affiliations

    • Professor and Chairman, Department of Oral and Maxillofacial Surgery, and Director of Oral and Maxillofacial Surgery Residency Program, University of Tennessee Medical Center and University of Tennessee Cancer Institute, Knoxville, TN
    • Corresponding Author InformationAddress correspondence and reprint requests to Dr Carlson: Department of Oral and Maxillofacial Surgery, University of Tennessee Medical Center, 1930 Alcoa Hwy, Suite 335, Knoxville, TN 37920
    • ,
  • John D. Basile, DMD

      Affiliations

    • Chief Resident, Department of Oral and Maxillofacial Surgery, University of Tennessee Medical Center, Knoxville, TN

References 

  1. Migliorati CA, Schubert MM, Peterson DE, et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone (An emerging oral complication of supportive cancer therapy). Cancer. 2005;104:83
  2. Rogers MJ, Watts DJ, Russel RGG. Overview of bisphosphonates. Cancer. 1997;80(suppl):1652
  3. Berenson JR. Bisphosphonates in multiple myeloma. Cancer. 1997;80:1661
  4. Lipton A. Bisphosphonates and breast carcinoma. Cancer. 1997;80:1668
  5. McClung MR. Bisphosphonates. Endocrinol Metab Clin North Am. 2003;32:253
  6. Naidu A, Dechow PC, Spears R, et al. The effects of bisphosphonates on osteoblasts in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;106:5
  7. Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res. 2003;9:2893
  8. Landesberg R, Cozin M, Cremers S, et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg. 2008;66:839
  9. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg. 2004;62:527
  10. Etminan M, Aminzadeh K, Matthew IR, et al. Use of oral bisphosphonates and the risk of aseptic osteonecrosis: A nested case-control study. J Rheumatol. 2008;35:1
  11. Koka S, Clarke BL, Amin S, et al. Oral bisphosphonate therapy and osteonecrosis of the jaw: What to tell the concerned patient. Int J Prosthodont. 2007;20:151
  12. Kyrgidis A, Vahtsevanos K, Koloutsos G. Bisphosphonate-related osteonecrosis of the jaws: A case-control study of risk factors in breast cancer patients. J Clin Oncol. 2008;26:1
  13. Wilkinson GS, Kuo YF, Freeman JL, et al. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: A population-based analysis. J Natl Cancer Inst. 2007;99:1016
  14. Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353:99
  15. Wang EP, Kaban LB, Strewler GJ, et al. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg. 2007;65:1328
  16. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol. 2005;23:8580
  17. Wessel JH, Dodson TB, Zavras A. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: A case-control study. J Oral Maxillofac Surg. 2008;66:625
  18. Zarynchanski R, Elphee E, Walton P, et al. Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol. 2006;81:73
  19. Hewitt C, Farah CS. Bisphosphonate-related osteonecrosis of the jaws: A comprehensive review. J Oral Pathol Med. 2007;36:319
  20. Woo SB, Hellstein JW, Kalmar JR. Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753
  21. Yarom N, Yahalom R, Shoshani Y, et al. Osteonecrosis of the jaw induced by orally administered bisphosphonates: Incidence, clinical features, predisposing factors and treatment outcome. Osteoporosis Int. 2007;18:1363
  22. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567
  23. In:  Marx RE editors. Oral & Intravenous Bisphosphonate-Induced Osteonecrosis of the Jaws (History, Etiology, Prevention, and Treatment). Quintessence Publishing: Chicago, IL; 2007;
  24. Ruggiero SL. Osteonecrosis. In:  Laskin DM,  Abubaker AO editor. Decision Making in Oral and Maxillofacial Surgery. Chicago, IL: Quintessence Publishing; 2007;p. 228–229
  25. Boonyapakorn T, Schirmer I, Reichart PA, et al. Bisphosphonate-induced osteonecrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 2008;44:857
  26. Dodson TB, Raje NS, Caruso PA, et al. Case 9-2008: A 65-year-old woman with a nonhealing ulcer of the jaw. N Engl J Med. 2008;358:1283
  27. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol. 2006;24:945
  28. Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention and treatment. J Oral Maxillofac Surg. 2007;65:2397
  29. Freiberger JJ, Padilla-Burgos R, Chhoeu AH, et al. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: A case series. J Oral Maxillofac Surg. 2007;65:1321
  30. Vescovi P, Merigo E, Meleti M, et al. Bisphosphonate-associated osteonecrosis (BON) of the jaws: A possible treatment? ([letter]). J Oral Maxillofac Surg. 2006;64:1460
  31. Migliorati CA, Casiglia J, Epstein J, et al. Managing the care of patients with bisphosphonate-associated osteonecrosis (An American Academy of Oral Medicine position paper). J Am Dent Assoc. 2005;136:1658
  32. Leite AF, Figueiredo PT, Melo NS, et al. Bisphosphonate-associated osteonecrosis of the jaws (Report of a case and literature review). Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102:14
  33. Nase JB, Suzuki JB. Osteonecrosis of the jaw and oral bisphosphonate treatment. J Am Dent Assoc. 2006;137:1115
  34. Adornato MC, Morcos I, Rozanski J. The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors. J Am Dent Assoc. 2007;138:971
  35. Levin L, Laviv A, Schwartz-Arad D. Denture-related osteonecrosis of the maxilla associated with oral bisphosphonate treatment. J Am Dent Assoc. 2007;138:1218
  36. Allen MR, Burr DB. Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg. 2008;66:987
  37. Junquera L, Gallego L. Nonexposed bisphosphonate-related osteonecrosis of the jaws: Another clinical variant?. J Oral Maxillofac Surg. 2008;66:1516

 Dr Carlson is a paid consultant for Novartis. Dr Basile states no financial arrangement or affiliation with a corporate organization or a manufacturer of a product discussed in this article.

PII: S0278-2391(09)00111-6

doi: 10.1016/j.joms.2009.01.006

Journal of Oral and Maxillofacial Surgery
Volume 67, Issue 5, Supplement , Pages 85-95 , May 2009

Article Tools

* Image Usage & Resolution